Key result
Mean platelet volume was higher in nSTEACS patients than healthy controls (11.0 vs 9.2 fL; P<0.001) but was not an independent predictor of cardiovascular death or new ACS at 6 months.
Why the study?
Does mean platelet volume (MPV) at admission independently predict cardiovascular death and new ACS at 6 months in patients with nSTEACS?
Population
329 patients with a diagnosis of non-ST-elevation acute coronary syndrome at admission, and 87 healthy…
Comparison
Mean platelet volume determination in the first… vs 87 healthy controls; comparison across MPV…
Design
Cohort
Follow-up
6-month
Authors
Loading...
MPV should not guide nSTEACS prognostication; leaves open its role in larger cohorts or combined risk models.
Observational (n=416)
Does mean platelet volume (MPV) at admission independently predict cardiovascular death and new ACS at 6 months in patients with nSTEACS?
Effect estimate: HR 1.4 (95% CI 1.1-1.8)
p-value: p=.018
While mean platelet volume is elevated in patients with nSTEACS compared to healthy controls, it does not serve as an independent prognostic marker for cardiovascular death or recurrent ACS at 6 months.
López‐Cuenca et al. (2011) conducted an observational in Non-ST-elevation acute coronary syndrome (nSTEACS) (n=416). Mean platelet volume (MPV) vs. Healthy controls was evaluated on Composite of cardiovascular death and new ACS (HR 1.4, 95% CI 1.1-1.8, p=.018). Mean platelet volume was higher in nSTEACS patients than healthy controls (11.0 vs 9.2 fL; P<0.001) but was not an independent predictor of cardiovascular death or new ACS at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: